Last reviewed · How we verify
NCT06983951
Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With Recurrent/Refractory Light Chain Amyloidosis
NA trial testing BCMA CART in Light Chain Amyloidosis in 30 participants. Currently enrolling.
30 September 2027
Quick facts
| Lead sponsor | Beijing Boren Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 20 February 2025 |
| Primary completion | 30 September 2027 |
| Estimated completion | 30 September 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- BCMA CART — full drug profile →
Conditions studied
- Light Chain Amyloidosis — all drugs for Light Chain Amyloidosis →
Sponsor
Beijing Boren Hospital
Who can join
18 and older, any sex, with Light Chain Amyloidosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a multicenter, open label, fixed dose exploratory clinical trial with an expected enrollment of 30 subjects. The main objective is to evaluate the safety of targeted BCMA autologous CART cell injection in the treatment of recurrent or refractory light chain amyloidosis in subjects, preliminarily verify the effectiveness of targeted BCMA autologous CART cell injection in the treatment of recurrent or refractory light chain amyloidosis in subjects, and explore the pharmacokinetic, pharmacodynamic, and immunogenic characteristics of targeted BCMA autologous CART cell injection after reinfusion.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Management of relapsed/refractory AL amyloidosis.
Ling J, Sidiqi MH, Gertz M. · · 2026 · PMID 41894688 · DOI 10.1182/bloodadvances.2025019223
Verify or expand the search:
- PubMed search for NCT06983951
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of BCMA CART
Trials testing the same drug.
- NCT07109323 — Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM · Phase 1, PHASE2 · recruiting
Other recruiting trials for Light Chain Amyloidosis
Currently open trials in the same condition.
- NCT07081646 — A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloido · Phase 1, PHASE2 · recruiting
- NCT06971380 — Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis · Phase 2 · recruiting
Other Beijing Boren Hospital trials
Trials by the same sponsor.
- NCT07502859 — A Study of BEN301 Injection in the Treatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
- NCT07448298 — A Clinical Study of AFN50 in the Treatment of Autoimmune Diseases · EARLY_PHASE1 · recruiting
- NCT06993493 — Autologous CD19CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases · NA · recruiting
- NCT06983964 — Safety and Efficacy of CD19 CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases · NA · recruiting
- NCT06661811 — A Study of CAR-T Cells Targeting Autoimmune Diseases · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06983951 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Boren Hospital
- Last refreshed: 21 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06983951.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing